Literature DB >> 28560507

Comparison of CROES, S.T.O.N.E, and Guy's scoring systems for the prediction of stone-free status and complication rates following percutaneous nephrolithotomy in patients with chronic kidney disease.

Fatih Yanaral1, Faruk Ozgor2, Metin Savun2, Murat Sahan2, Omer Sarilar2, Murat Binbay2.   

Abstract

PURPOSE: To evaluate and compare the accuracy of S.T.O.N.E, Clinical Research Office of the Endourological Society (CROES), and Guy's stone score in patients with chronic kidney disease (CKD) following percutaneous nephrolithotomy (PNL).
METHODS: The charts of patients who had undergone a prone percutaneous nephrolithotomy from June 2006 to June 2016 were retrospectively analyzed. Patients accepted as stage 3 and higher according to chronic kidney disease epidemiology collaboration formula, were enrolled into the study. Calculation of the CROES, S.T.O.N.E, and Guy's scoring system (SS) was made as defined in original papers. Patients were categorized into four scores according to CROES, into nine scores according to S.T.O.N.E, and into four scores according to Guy's SS.
RESULTS: A total of 303 patients fulfilled the study inclusion criteria. The mean preoperative eGFR and creatinine levels were 47 mL/min and 1.55 mg/dL, respectively. In patients who were stone free and those with residual stones, the mean CROES SS was 179 and 137 (p < 0.001), the mean S.T.O.N.E score was 8.8 and 9.9 (p < 0.001), and the mean Guy's SS was 1.8 and 2.4 (p < 0.001), respectively. Multivariate regression analysis revealed CROES SS was the only scoring system, which had a predictive value for PNL outcome in patients with CKD (p = 0.011) and any of three SS were not useful for predicting PNL complications in patients with CKD.
CONCLUSION: Our study demonstrated the CROES SS was the only independent factor in the prediction of PNL outcome in CKD patients. Furthermore, three of the NSSs were not useful for predicting PNL complications in patients with CKD.

Entities:  

Keywords:  Kidney; Lithotripsy; Nephrolithiasis; Nephrostomy, percutaneous; Nomograms; Prognosis; Renal insufficiency, chronic

Mesh:

Year:  2017        PMID: 28560507     DOI: 10.1007/s11255-017-1631-x

Source DB:  PubMed          Journal:  Int Urol Nephrol        ISSN: 0301-1623            Impact factor:   2.370


  21 in total

Review 1.  EAU Guidelines on Diagnosis and Conservative Management of Urolithiasis.

Authors:  Christian Türk; Aleš Petřík; Kemal Sarica; Christian Seitz; Andreas Skolarikos; Michael Straub; Thomas Knoll
Journal:  Eur Urol       Date:  2015-08-28       Impact factor: 20.096

2.  External Validation of CROES Nephrolithometry as a Preoperative Predictive System for Percutaneous Nephrolithotomy Outcomes.

Authors:  Stavros Sfoungaristos; Ofer N Gofrit; Vladimir Yutkin; Ezekiel H Landau; Dov Pode; Mordechai Duvdevani
Journal:  J Urol       Date:  2015-08-24       Impact factor: 7.450

3.  Prediction of single procedure success rate using S.T.O.N.E. nephrolithometry surgical classification system with strict criteria for surgical outcome.

Authors:  Arash Akhavein; Carl Henriksen; Jamil Syed; Vincent G Bird
Journal:  Urology       Date:  2015-01       Impact factor: 2.649

4.  S.T.O.N.E. nephrolithometry: novel surgical classification system for kidney calculi.

Authors:  Zhamshid Okhunov; Justin I Friedlander; Arvin K George; Brian D Duty; Daniel M Moreira; Arun K Srinivasan; Joel Hillelsohn; Arthur D Smith; Zeph Okeke
Journal:  Urology       Date:  2013-03-26       Impact factor: 2.649

5.  Evaluation of CROES Nephrolithometry Nomogram as a Preoperative Predictive System for Percutaneous Nephrolithotomy Outcomes.

Authors:  Sumit Kumar; Jayaram Sreenivas; Vilvapathy Senguttuvan Karthikeyan; Ashwin Mallya; Ramaiah Keshavamurthy
Journal:  J Endourol       Date:  2016-09-22       Impact factor: 2.942

6.  ESRD caused by nephrolithiasis: prevalence, mechanisms, and prevention.

Authors:  Paul Jungers; Dominique Joly; Frédéric Barbey; Gabriel Choukroun; Michel Daudon
Journal:  Am J Kidney Dis       Date:  2004-11       Impact factor: 8.860

7.  Improved renal function following aggressive treatment of urolithiasis and concurrent mild to moderate renal insufficiency.

Authors:  M Gupta; D M Bolton; P N Gupta; M L Stoller
Journal:  J Urol       Date:  1994-10       Impact factor: 7.450

8.  Left ventricular hypertrophy and chronic fluid overload in peritoneal dialysis patients.

Authors:  Rizna Abdul Cader; Osama Ali Ibrahim; Samir Paul; Halim Abdul Gafor; Rozita Mohd
Journal:  Int Urol Nephrol       Date:  2013-12-05       Impact factor: 2.370

Review 9.  Associations of kidney disease measures with mortality and end-stage renal disease in individuals with and without diabetes: a meta-analysis.

Authors:  Caroline S Fox; Kunihiro Matsushita; Mark Woodward; Henk J G Bilo; John Chalmers; Hiddo J Lambers Heerspink; Brian J Lee; Robert M Perkins; Peter Rossing; Toshimi Sairenchi; Marcello Tonelli; Joseph A Vassalotti; Kazumasa Yamagishi; Josef Coresh; Paul E de Jong; Chi-Pang Wen; Robert G Nelson
Journal:  Lancet       Date:  2012-09-24       Impact factor: 79.321

10.  Prospective evaluation of complications using the modified Clavien grading system, and of success rates of percutaneous nephrolithotomy using Guy's Stone Score: A single-center experience.

Authors:  Swarnendu Mandal; Apul Goel; Rohit Kathpalia; Satyanarayan Sankhwar; Vishwajeet Singh; Rahul J Sinha; Bhupender P Singh; Divakar Dalela
Journal:  Indian J Urol       Date:  2012-10
View more
  2 in total

Review 1.  Research progress of percutaneous nephrolithotomy.

Authors:  Chao Wei; Yucong Zhang; Gaurab Pokhrel; Xiaming Liu; Jiahua Gan; Xiao Yu; Zhangqun Ye; Shaogang Wang
Journal:  Int Urol Nephrol       Date:  2018-03-19       Impact factor: 2.370

2.  Study on risk factors, bacterial species, and drug resistance of acute pyelonephritis associated with ureteral stent after percutaneous nephrolithotomy.

Authors:  Guo Jiang; Jiang Li; He Long; Chen Qiulin; Ren Jin; Yang Yaodong; Dong Xingyou; Zhao Jiang; Zhang Zhenyang
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2020-10-09       Impact factor: 3.267

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.